repeat expansion mutation rescues RNA foci formation and promoter hypermethylation without altering C9orf72 transcript and protein expression.
Introduction
The most frequent genetic cause of Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) is a hexanucleotide (GGGGCC) repeat expansion in the chromosome 9 open reading frame 72 (C9orf72) gene (1, 2) . The repeat lies between two alternative non-coding first exons of this gene known only to have structural similarities to the DENN (differentially expressed in normal and neoplastic cells) family of Rab GEFs (3) . Affected carriers can have up to hundreds to thousands of repeats, though the number is highly variable, even within an individual (4) . Normal individuals are generally thought to have less than about 30 repeats, however a definitive threshold for pathogenicity is not currently established (1, 2, 5) .
The precise mechanisms underlying C9orf72-linked neurodegeneration remain unclear.
The location of the mutation within a non-coding regulatory region points towards haploinsufficiency as a pathogenic mechanism. Early reports indeed showed a reduction in C9orf72 transcription (1, 6), which was observed in a number of subsequent studies along with decreased protein expression (7) (8) (9) (10) (11) and hypermethylation of both CpG islands and histones proximal to the repeat expansion (5, (12) (13) (14) . Additionally, knockout of the C9orf72 ortholog in zebrafish and C. elegans resulted in motor deficits and neurodegeneration (11, 15) . However, deletion of C9orf72 in mice did not produce neurodegeneration, motor deficits, or decreased survival (16) , and knockdown of C9orf72 in human iPS cell-derived neurons did not alter viability (17) . Together with the lack of any disease-causing coding mutations in the gene, the role of the C9orf72 protein in disease pathogenesis, if any, is still uncertain (18) .
Transcription of the repeat itself yields an RNA species with extensive secondary structures that aggregate to form nuclear RNA foci (1). These foci are thought to confer a toxic gain of function by sequestering essential RNA binding proteins, similar to the sequestration of Muscleblind in myotonic dystrophy (9, 17, (19) (20) (21) . Furthermore, there is evidence that these repeat-containing RNAs form G-quadruplex structures which disrupt transcription and nucleocytoplasmic transport (22, 23) . However, a Drosophila model expressing exclusively C9orf72 RNA foci showed very little toxicity (24) .
Repeat-associated non-canonical (RAN) translation, where the repeat is translated in all three reading frames independent of a start site, is now known to occur in most repeat expansion disorders (25) . RAN translation of the hexanucleotide repeat in C9orf72 produces poly-dipeptide chains of GP, GA, and GR from the sense transcript and PA, PR, and PG from the antisense strand (26) (27) (28) . In the diseased brain, these dipeptides form p62-positive intracellular inclusions reminiscent of other neurodegenerative proteinopathies, however studies vary on their toxicity and relevance to pathogenesis.
Overexpression in cell cultures revealed a greater aggregation potential for the GA species, inducing neuronal toxicity through ER stress, and disruption of the proteasomal pathway (29, 30) . In Drosophila, GA expression is relatively innocuous while the arginine-containing species, GR and PR, induced striking neurodegeneration (31) (32) (33) .
Interestingly, human patient expression of the dipeptide products does not seem to correlate well with the pattern of degeneration or clinical phenotype (34) (35) (36) . In fact, dipeptide deposition and foci formation seem to appear long before clinical symptoms manifest, and are also present in clinically normal patients who have only about 30 repeats (37, 38) . Furthermore, the recent creation of BAC transgenic mice by two independent labs showed the presence of the foci and dipeptide inclusions without neurodegeneration or any behavioral or motor phenotypes (39, 40) .
Regardless of the mechanisms, it remains clear that the repeat expansion in C9orf72 is responsible for the majority of FTD and ALS, up to 6% of sporadic cases and 25% and 40% of familial cases of FTD and ALS respectively (41) . Advances in genome editing with the availability of CRISPR technology bring wide possibilities in disease modeling and gene therapy by enabling precise and efficient DNA double-stranded breaks (42) . Recently, this system was shown in vivo to partially rescue deficits in a mouse model of Duchenne muscular dystrophy (43) (44) (45) . Here we show the excision of the full hexanucleotide repeat expansion from FTD patient-derived iPS cells using the CRISPR-Cas9 system. Deletion of the expanded repeat rescued RNA foci formation and the promoter hypermethylation observed in repeat expansion carrier cells, while having little effect on the transcription and protein expression of C9orf72.
Results

Generation and characterization of iPS cell lines
Human dermal fibroblasts from C9orf72 repeat-positive FTD/ALS patients were reprogrammed using the hSTEMCCA polycistronic lentiviral system (46) . Individual lines were verified for pluripotency through immunofluorescent expression of the markers SSEA4, TRA-1-81, NANOG, and OCT4 ( Figure S1 ). Cells were able to differentiate into the three germ layers by in vitro embryoid body (EB) formation ( Figure S2 ), and the microarray-based online PluriTest assay (www.pluritest.org, (47)) further confirmed the pluripotency of the lines ( Figure S3 ). Directed neuronal differentiation using the EB intermediate method efficiently produced Nestin-and PAX6-positive neural progenitor cells (NPCs, Figure S4 ), which further differentiated into βIII-tubulin-positive neurons and GFAP-positive glial cells ( Figure S5 ).
All the patient-derived cells retained the large repeat expansion mutation. Southern blotting revealed bands between 7 and 8.5kb, corresponding to repeat sizes between 750 and 1000 units. Reprogramming to iPS cells and differentiation to NPCs and neurons yielded various fragment sizes suggesting instability of the repeat, both increasing and decreasing in size by hundreds of repeats ( Figure S6 ). Other groups have similarly observed this repeat instability within cell lines, along with somatic mosaicism within affected patients (4, 17, 48) .
CRISPR design and repeat knockout generation
In order to excise the repeat expansion, we used the CRISPR-Cas9 genome editing system with two guide RNAs designed to target 4 base pairs (bp) upstream and 49 bp downstream of the hexanucleotide repeat ( Figure 1a ). These sites were selected using a web-based software tool that minimizes potential off-target effects (http://crispr.mit.edu/) (49) . Each was cloned into the px330 human-optimized CRISPR-Cas9 plasmid (50) and introduced to the iPS cells by nucleofection. Subsequent PCR of the region surrounding the repeat showed an amplicon of approximately 65 bp smaller than the normal expected size, indicating simultaneous cleavage and removal of the spanning region by non-homologous end-joining (NHEJ) ( Figure 1b ).
Cells were passaged at clonal density and single iPS cell colonies were screened for the presence of the deletion band and the absence of the expansion mutation by Repeat-Primed (RP)-PCR. Out of 593 colonies picked from multiple different parent lines, 66 (11.1%) contained a deletion band. Sequencing of this band showed the repeat region was successfully targeted, though the accuracy of the nuclease and/or repair varied among the clones, with some lines losing as many as 23 additional nucleotides ( Figure   1c ). Further selection was repeated to obtain homogeneity, until clones were negative for either the wild type amplicon or the stutter pattern in the RP-PCR ( Figure 2 ). 5 lines from 2 patients have been obtained thus far. One of the mutant parent lines (Line A) originally had an expansion of around 845 repeats and a normal allele with 2 repeats (+/exp). From this line, 4 clones were isolated (A50, A51, A65, A80) that were negative for the repeat when tested by RP-PCR ( Figure 2b Southern blots confirmed that our CRISPR treatment effectively induced the complete and permanent loss of the C9orf72 repeat expansion mutation in the 4 clones from parent A (A50, A51, A65, A80), while clone B13 retained the expansion mutation ( Figure   2c ).
These repeat knockout (ReKO) iPS cells retained their pluripotency and remained free from karyotype abnormalities ( Figure S7 ). SNP genotyping showed an overall concordance rate of >99.99% (discordance rate of 8.3 e-5) across unedited parent and ReKO lines derived from the same patient. By contrast, the concordance between these and additional genotype data from a number of different patients was on average 74.63%, thus validating that our parent and ReKO lines indeed originated from the same biological specimen.
No off-target genome editing observed in high-probability cleavage sites
Previous studies have demonstrated that CRISPR-Cas9 RNA-guided nucleases are capable of inducing off-target mutations with a highly variable frequency, sometimes exceeding even those of the intended locus (48) . To ensure that the observed phenotypic difference in our ReKO lines are not the epistatic effect of one or more unintended offtarget mutations, we performed whole-genome sequencing (WGS) followed by indel calling for comparative analysis between the parent and ReKO-A50 lines. As the specificity of off-target mutagenesis detected by WGS is inherently limited by the baseline accuracy of indel calling of our NGS processing pipeline, we limited our search space to the top 1000 computationally-determined off-target cleavage sites for each guide RNA target sequence, respectively. Only six of the 1,959 top potential off-target sites examined displayed evidence for the putative presence of an indel with respect to the parent line, none of which passed typical quality filters for WGS genotyping.
Deletion of the repeat expansion corrects RNA foci formation but RAN dipeptides are not observed
One of the cellular hallmarks of the C9orf72 repeat expansion mutation is the expression of RNA foci through the transcripts initiating upstream of the repeat at exon 1a (1, 2, 17, 27, 45) . Consistent with these findings, RNA foci, both in the sense and antisense direction, were detected in repeat carrier iPS cell lines, as well as differentiated neurons ( Figure S8 ). CRISPR-mediated deletion of the repeat expansion effectively prevented RNA foci formation in these cells, whereas cells with the deletion on the normal unexpanded allele continued to exhibit foci ( Figure 3a ).
RAN dipeptide deposition is another unique pathological hallmark of C9orf72-related neurodegenerative diseases. Aberrant translation of the hexanucleotide repeat generates large repeating dipeptide products that aggregate to form intracellular inclusions in the brains of affected patients (26, 28) . In spite of this, RAN dipeptide products were not observed in our iPS cell-derived neurons when examined by immunofluorescence (not shown). Similarly, dot blots were unable to detect any significant RAN dipeptide production in our neuronal cultures ( Figure 3b ).
Deletion of the repeat expansion rescues hypermethylation at the C9orf72 locus
Other non-coding repeat expansion mutations are thought to cause disease through epigenetically-mediated downregulation of expression. In the case of Fragile X Syndrome, a CGG repeat expansion in the 5' untranslated region of FMR1 leads to DNA hypermethylation and deficiency of the protein (52, 53) . Likewise, the C9orf72 repeat lies within a GC-rich region that harbors CpG islands previously found to be hypermethylated in ~10-35% of C9-FTD and ALS patient blood samples (5, 13) . Bisulfite conversion and sequencing of our cells showed that CpG hypermethylation is indeed present in iPS cells and neurons carrying the expansion mutation ( Figure 4 ).
Quantification of the methylation through pyrosequencing showed that the deletion of the expanded repeat resulted in reduction of methylation in all 4 ReKO lines to levels resembling non-carrier controls. Deletion of the normal allele did not reverse the hypermethylation indicating that the effect is due to the expansion of the repeat and is rescued with its deletion by our CRISPR constructs (Figure 4b , Figure S9 , Table S1 ).
Knockout of the C9orf72 repeat expansion mutation does not alter C9orf72 expression
Because our repeat deletion strategy is targeting a regulatory region of C9orf72, it is possible that this intervention may disrupt normal expression. If haploinsufficiency of C9orf72 is indeed contributing to disease, further interference with a regulatory region may exacerbate disease progression, especially if the normal allele is also targeted. On the other hand, the repeat expansion itself was reported to be hypermethylated and associated with downregulation of transcription (12) . If this expansion mutation indeed introduces a negative regulatory element, deletion of this region may be beneficial.
C9orf72 protein levels were examined in our iPS cell-derived neurons and no significant difference was observed in neurons containing the repeat mutation (Figure 5a 
Discussion
Here we demonstrated the capability of the CRISPR-Cas9 system to permanently delete the large repeat expansion mutation in C9orf72-associated disease. Using two guide
RNAs targeting regions flanking the repeat expansion, simultaneous cleavage was able to remove a full expansion mutation, completely prevent formation of RNA foci, and rescue local hypermethylation. Multiple lines were generated targeting both alleles, but none of the clones isolated thus far contained homozygous deletions. The deleted allele often contained small additional indels typical of repair by NHEJ (54), but because the targeted region is within an intronic region away from splice sites, these deletions may have little or no effect on gene expression. Indeed, loss of this repeat region did not significantly alter expression of C9orf72, which may be of relevance given the recent discovery of its role in microglia and inflammation (55) . The rescue from promoter hypermethylation is particularly interesting because multiple studies have reported its function in reducing expression of C9orf72 (5, 12, 13) . Although this downregulation is hypothesized to cause disease through haploinsufficiency, it has also been suggested to be neuroprotective through the consequential reduction in RNA foci and RAN dipeptide production (56, 57) . If in the diseased patient this hypermethylation does contribute to pathogenesis, then targeting the repeat expansion for deletion using CRISPRs may be a more favorable strategy. Attempts to target the repeat using antisense oligonucleotides would not be able to rescue this haploinsufficiency (17) , and simultaneously targeting both the sense and antisense products of the repeat may be difficult given their complementary sequence. Our results here show that RNA foci expression and promoter hypermethylation can be blocked while preserving endogenous protein expression.
Although our CRISPR strategy was able to preserve C9orf72 expression, we did not observe an increase in expression with the rescue of promoter hypermethylation as expected. Actually, we did not observe any deficit in transcript or protein expression in our C9orf72 mutant cell lines despite having hypermethylation. This discrepancy remains unclear, but it does suggest a more complex mechanism of transcriptional regulation than methylation alone. Together with the lack of RAN dipeptide expression, this suggests the mutation alone is not sufficient to induce haploinsufficiency or RAN dipeptide deposition, at least in our cell culture system, though it is important to note that iPS cell-derived neurons resemble fetal neurons and may not be the best model for the aged diseased brain (58) . It is possible the effects of the mutation may take decades to accumulate or may arise in a non-cell-autonomous manner. Our cells did however exhibit the RNA foci that are characteristic of these repeat expansion disorders, but their presence in these viable embryonic-like cells argues against a primary role in pathogenesis. Nonetheless, they do provide a valuable readout for the presence and transcription of the repeat expansion mutation.
Regardless of whether the C9orf72 repeat expansion mutation acts through a gain-oftoxicity or loss-of-function, our strategy of deleting the entire repeat expansion itself may resolve both. Furthermore, if disease severity is indeed correlated with repeat size, removing the entire repeat should prevent the unstable somatic expansion that is common in these repeat diseases. We demonstrated the feasibility of targeted genomic editing to excise the repeat expansion region, reversing cellular phenotypes while preserving C9orf72 mRNA and protein expression in vitro. Whether this mutation is a viable target in vivo is a question for future studies when models of disease become available. BAC mice exhibit RNA foci and RAN dipeptide deposition but not behavioral deficits or neurodegeneration (39, 40) . Targeting the repeat in vivo would likely require Adeno-Associated Viral (AAV) delivery, which has low immunogenicity, has already been demonstrated in murine CNS (59) , and is already used in the clinic (60, 61) . This strategy of deleting repeat expansions may be applicable to other similar diseases with intronic non-coding repeats, such as Fragile X or Friedreich's Ataxia. The use of NHEJ, though more efficient than homologous recombination, often produces indels, which may be disastrous if not for its occurrence in non-coding regions, and we have shown that the normal gene expression can be preserved. Translation into the clinic would still follow the advancement of CRISPR technology, when improvements in genome editing and safety are demonstrated in patients.
Materials and Methods
Induced pluripotent stem cell generation. Repeat expansion genotyping. The presence of the C9orf72 repeat expansion was determined using the repeat-primed PCR assay as described in (1). Southern blotting was performed as described in (1) Protein lysates were quantified by BCA assay (Biorad) and spotted on a dot blot or separated by electrophoresis prior to western transfer. Quantification was done manually using ImageJ.
Fluorescence in situ hybridization (FISH) . FISH was performed as described in (17) .
Briefly, cells on coverslips were fixed in 4% paraformaldehyde (Electron Microscopy Services) and permeabilized using 0.25% Triton X-100. Cells were washed using RNAse- Supplementary Table   Table S1 . Quantification of C9orf72 promoter CpG sites by pyrosequencing. 
